Targeting NRF2 signaling for cancer chemoprevention
- College of Pharmacy, Yeungnam University, 214-1 Dae-dong, Gyeongsan-si, Gyeongsangbuk-do 712-749 (Korea, Republic of)
- Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (United States)
Modulation of the metabolism and disposition of carcinogens through induction of cytoprotective enzymes is one of several promising strategies to prevent cancer. Chemopreventive efficacies of inducers such as dithiolethiones and sulforaphane have been extensively studied in animals as well as in humans. The KEAP1-NRF2 system is a key, but not unilateral, molecular target for these chemopreventive agents. The transcription factor NRF2 (NF-E2-related factor 2) is a master regulator of the expression of a subset of genes, which produce proteins responsible for the detoxication of electrophiles and reactive oxygen species as well as the removal or repair of some of their damage products. It is believed that chemopreventive enzyme inducers affect the interaction between KEAP1 and NRF2 through either mediating conformational changes of the KEAP1 protein or activating phosphorylation cascades targeting the KEAP1-NRF2 complex. These events in turn affect NRF2 stability and trafficking. Recent advances elucidating the underlying structural biology of KEAP1-NRF2 signaling and identification of the gene clusters under the transcriptional control of NRF2 are facilitating understanding of the potential pleiotropic effects of NRF2 activators and discovery of novel classes of potent chemopreventive agents such as the triterpenoids. Although there is appropriately a concern regarding a deleterious role of the KEAP1-NRF2 system in cancer cell biology, especially as the pathway affects cell survival and drug resistance, the development and the use of NRF2 activators as chemopreventive agents still holds a great promise for protection of normal cells from a diversity of environmental stresses that contribute to the burden of cancer and other chronic, degenerative diseases.
- OSTI ID:
- 21344908
- Journal Information:
- Toxicology and Applied Pharmacology, Vol. 244, Issue 1; Other Information: DOI: 10.1016/j.taap.2009.08.028; PII: S0041-008X(09)00372-X; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0041-008X
- Country of Publication:
- United States
- Language:
- English
Similar Records
A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways
Nrf2 protects against airway disorders
Related Subjects
ANISOLE
ANTHRACENE
CARCINOGENS
CONFORMATIONAL CHANGES
DEXTRAN
DIMETHYLBENZANTHRACENE
GENES
GLUTATHIONE
MEN
NEOPLASMS
OXIDOREDUCTASES
PHOSPHORYLATION
PYRENE
QUININE
TOLUENE
TRANSCRIPTION FACTORS
ALKALOIDS
ALKYLATED AROMATICS
ANIMALS
ANTI-INFECTIVE AGENTS
ANTIMICROBIAL AGENTS
ANTIPYRETICS
AROMATICS
BLOOD SUBSTITUTES
CARBOHYDRATES
CENTRAL NERVOUS SYSTEM AGENTS
CENTRAL NERVOUS SYSTEM DEPRESSANTS
CHEMICAL REACTIONS
CONDENSED AROMATICS
DISEASES
DRUGS
ENZYMES
ETHERS
HEMATOLOGIC AGENTS
HYDROCARBONS
MALES
MAMMALS
MAN
ORGANIC COMPOUNDS
ORGANIC OXYGEN COMPOUNDS
PEPTIDES
POLYPEPTIDES
POLYSACCHARIDES
PRIMATES
PROTEINS
RADIOPROTECTIVE SUBSTANCES
RESPONSE MODIFYING FACTORS
SACCHARIDES
VERTEBRATES